Martin Dymek joins Straumann as Regional Head of North America
Basel/Andover, 15 July 2009: Straumann announced today that Mr Martin Dymek has joined the company as Regional Head North America, based in Andover, Massachusetts.
Martin Dymek’s career in the dental industry spans almost thirty years and includes multiple senior managerial positions. He has a proven track record in business development and growth, mergers and acquisitions, and operational management.
He joins Straumann from IOS Technologies, a developer of cutting-edge intra-oral scanning technologies. Prior to IOS Technologies, where he was CEO, he advised decision makers in investment and dental companies including the Blackstone Group and Novalar Pharmaceuticals.
After graduating from Cornell University, he began his career at the Japanese Shofu Dental Corporation, where he became Marketing Director for the Americas. In 1990, he moved to Steri-Oss, where he held several management positions and led the management buyout from Bausch and Lomb in 1996. He became President of Steri-Oss, which was subsequently acquired by Nobel Biocare in 1998. He was then appointed President of Nobel Biocare USA Inc. and held full profit-and-loss accountability for the entire North and South American business until 2004.
Martin Dymek’s longstanding success as a leader in the dental industry is impressive. So too is his extensive network in the American market. These are just two of many qualities that make him a valuable addition to Straumann and its North American team.
Disclaimer
This release contains certain “forward-looking statements”. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group’s products, the potential for the Group’s products to become obsolete, the Group’s ability to defend its intellectual property, the Group’s ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group’s ability to generate revenues and profitability, and the Group’s ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.
